Fig. 1: Correlation of elevated expression of SLC39A10 with poor clinical outcomes in gastric cancer patients.

a The mRNA expression of SLC39A family members in gastric adenocarcinomas (GAs) and normal gastric tissues (NTs) or the matched noncancerous tissues (MNs) (data from the TCGA RNA-Seq dataset). b The mRNA expression of SLC30A family members in GAs and NTs or MNs (data from the TCGA RNA-Seq dataset). A significant association of increased expression of SLC39A10 with poor patient survival in the TCGA dataset (c) and two GEO datasets (GSE15459 and GSE62254) (d) was found using Kaplan‒Meier Plotter. The box plots show the expression level of SLC39A10 in GA tumors of different sizes (e), lymph node metastasis statuses (f) and stages (g) (data from the TCGA database). The horizontal lines indicate the median value. h qRT‒PCR results showing the mRNA expression of SLC39A10 in GAs and the matched noncancerous gastric tissues (MN; n = 20). The SLC39A10 expression level was normalized to the 18 S rRNA level. The data were compared using a two-tailed paired t test. i Representative images showing immunohistochemical (IHC) staining of SLC39A10 on histologic slides of GAs and MNs in the left panel. The percentage of SLC39A10-positive cells is shown in the right panel. The error bars indicate the SDs. *P < 0.05; **P < 0.01; ***P < 0.001. Scale bar, 200 µm.